21 February 2023

CBMR publications and media appearances in January 2023

Media & Publications

Every month we release a full list of publications from the Center, as well as media appearances by the Center scientists

CBMR media and publications logo



Barrès Group
Christensen DL, et al. Environmental exposures are important for type 2 diabetes pathophysiology in sub-Saharan African populations. Diabetologia. 2023 Jan 19. doi: 10.1007/s00125-022-05867-3. Epub ahead of print.


Bäckhed Group
Kennedy KM, et al. Questioning the fetal microbiome illustrates pitfalls of low-biomass microbial studies. Nature. 2023 Jan;613(7945):639-649. doi: 10.1038/s41586-022-05546-8. Epub 2023 Jan 25.

Molnar D, et al. Pre-diabetes is associated with attenuation rather than volume of epicardial adipose tissue on computed tomography. Sci Rep. 2023 Jan 28;13(1):1623. doi: 10.1038/s41598-023-28679-w.


Emanuelli, Gerhart-Hines, Moritz Groups & Metabolomics Platform
Rupar K, et al. Full activation of thermogenesis in brown adipocytes requires Basigin action. FEBS J. 2023 Jan 3. doi: 10.1111/febs.16716. Epub ahead of print.


Grarup Group
Broadaway KA, et al. Loci for insulin processing and secretion provide insight into type 2 diabetes risk. Am J Hum Genet. 2023 Feb 2;110(2):284-299. doi: 10.1016/j.ajhg.2023.01.002. Epub 2023 Jan 23.


Grarup & Hansen Groups
Thuesen ACB, et al. A novel splice-affecting HNF1A variant with large population impact on diabetes in Greenland. Lancet Reg Health Eur. 2022 Nov 11;24:100529. doi: 10.1016/j.lanepe.2022.100529.


Guasch Group
Razquin C, et al. Circulating Amino Acids and Risk of Peripheral Artery Disease in the PREDIMED Trial. Int J Mol Sci. 2022 Dec 23;24(1):270. doi: 10.3390/ijms24010270.


Hansen Group
Allesøe RL, et al. Discovery of drug-omics associations in type 2 diabetes with generative deep- learning models. Nat Biotechnol. 2023 Jan 2. doi: 10.1038/s41587-022-01520-x. Epub ahead of print.

Laursen ASD, et al. Birth weight, childhood body mass index, and risk of diverticular disease in adulthood. Int J Obes (Lond). 2023 Jan 25. doi: 10.1038/s41366-023-01259-8. Epub ahead of print.

Stinson SE, et al. High Plasma Levels of Soluble Lectin-like Oxidized Low-Density Lipoprotein Receptor-1 Are Associated With Inflammation and Cardiometabolic Risk Profiles in Pediatric Overweight and Obesity. J Am Heart Assoc. 2023 Feb 7;12(3):e8145. doi: 10.1161/JAHA.122.027042. Epub 2023 Jan 25.

Thirion F, et al. The gut microbiota in multiple sclerosis varies with disease activity. Genome Med. 2023 Jan 5;15(1):1. doi: 10.1186/s13073-022-01148-1.

Vinther JL, et al. Gestational age at birth and body size from infancy through adolescence: An individual participant data meta-analysis on 253,810 singletons in 16 birth cohort studies. PLoS Med. 2023 Jan 26;20(1):e1004036. doi: 10.1371/journal.pmed.1004036.


Juul Holst Group
Brodersen K, et al. Comparable Effects of Sleeve Gastrectomy and Roux-en-Y Gastric Bypass on Basal Fuel Metabolism and Insulin Sensitivity in Individuals with Obesity and Type 2 Diabetes. J Diabetes Res. 2022 Dec 21;2022:5476454. doi: 10.1155/2022/5476454.

Gabe MBN, et al. Biased GLP-2 agonist with strong G protein-coupling but impaired arrestin recruitment and receptor desensitization enhances intestinal growth in mice. Br J Pharmacol. 2023 Jan 22. doi: 10.1111/bph.16040. Epub ahead of print.

Hagelqvist PG, et al. Exercise-related hypoglycaemia induces QTc-interval prolongation in individuals with type 1 diabetes. Diabetes Obes Metab. 2023 Jan 2. doi: 10.1111/dom.14964. Epub ahead of print.

Holst JJ. Glucagon 100 years. Important, but still enigmatic. Peptides. 2023 Mar;161:170942. doi: 10.1016/j.peptides.2023.170942. Epub 2023 Jan 7.

Holst JJ. Incretin-based therapy of metabolic disease. Dan Med J. 2022 Dec 21;70(1):A10220597.

Jørgensen NT, et al. Glucose metabolism, gut-brain hormones, and acromegaly treatment: an explorative single centre descriptive analysis. Pituitary. 2023 Feb;26(1):152-163. doi: 10.1007/s11102-022-01297-x. Epub 2023 Jan 6.

Kjeldsen SAS, et al. Development of a glucagon sensitivity test in humans: Pilot data and the GLUSENTIC study protocol. Peptides. 2023 Mar;161:170938. doi: 10.1016/j.peptides.2022.170938. Epub 2022 Dec 31.

Krogh LSL, et al. The naturally occurring GIP(1-30)NH2 is a GIP receptor agonist in humans. Eur J Endocrinol. 2023 Jan 10;188(1):lvac015. doi: 10.1093/ejendo/lvac015.

van Deuren T, et al. Butyrate and hexanoate-enriched triglycerides increase postprandrial systemic butyrate and hexanoate in men with overweight/obesity: A double-blind placebo-controlled randomized crossover trial. Front Nutr. 2023 Jan 4;9:1066950. doi: 10.3389/fnut.2022.1066950. 


Juul Holst, Treebak & Zierath Groups
Ashcroft SP, et al. Protocol to assess arteriovenous differences across the liver and hindlimb muscles in mice following treadmill exercise. STAR Protoc. 2023 Jan 3;4(1):101985. doi: 10.1016/j.xpro.2022.101985. Epub ahead of print.


Kilpeläinen Group
Tziomalos K, et al. Editorial: With obesity becoming the new normal, what should we do? -Volume II. Front Endocrinol (Lausanne). 2022 Dec 28;13:1119910. doi: 10.3389/fendo.2022.1119910.


Moritz Group
Gheibi S, et al. Reduced expression level of protein phosphatase, PPM1E, serves to maintain insulin secretion in type 2 diabetes. Diabetes. 2023 Jan 20:db220472. doi: 10.2337/db22-0472. Epub ahead of print.


Sakamoto Group
Battey E, et al. Myonuclear alterations associated with exercise are independent of age in humans. J Physiol. 2023 Jan 4. doi: 10.1113/JP284128. Epub ahead of print.

Hoefner C, et al. FK506-Binding Protein 2 Participates in Proinsulin Folding. Biomolecules. 2023 Jan 11;13(1):152. doi: 10.3390/biom13010152.


Treebak Group
Chubanava S & Treebak JT. Regular exercise effectively protects against the aging-associated decline in skeletal muscle NAD content. Exp Gerontol. 2023 Jan 25;173:112109. doi: 10.1016/j.exger.2023.112109. Epub ahead of print.